Spectrum Pharmaceuticals, Inc. Selects DSG For Blended Saas And Tech Transfer EDC

—DSG to expand established collaboration on EDC with Spectrum Pharmaceuticals—

MALVERN, Pa.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, for its Phase 3 pivotal oncology studies over the past three years, has engaged DSG for full service EDC, IWRS and data management services, including a rescue study. Recently, Spectrum personnel trained on DSG’s Designer tool to begin building earlier phase studies independently of DSG.

“Spectrum has been an extraordinary full-service clinical data capture and management client over the years with a dynamic oncology portfolio”

DSG’s award-winning EDC software, eCaseLink™, provides system builders with an intuitive tool, DSG Designer, enabling application of unlimited quantities of cross-visit edits on eCRFs without compromising system performance, a proprietary technology unique to DSG. Other features include risk-based and remote monitoring, 3rd-party system data integration, module for managing local lab Normals, integrated MedDRA/WHO drug auto-interactive encoder, ad-hoc reporting, SAS datasets on demand, patient profiles, protocol deviations, image upload and management, unlimited auto-emails, and auto-population between eCRFs.

Spectrum is also taking full advantage of DSG eCaseLink’s Innovation Award-winning IWRS and Data Management dashboard with round-the-clock support from DSG, one of the industry’s oldest and most experienced EDC providers.

“Spectrum has been an extraordinary full-service clinical data capture and management client over the years with a dynamic oncology portfolio,” said Tony Varano, CEO of DSG. “Now with DSG’s team building some EDC systems and Spectrum’s team building others, both teams are reaping the benefits of a common data platform with systems that site users, clinical personnel, CROs, data managers, and statisticians feel has all of the functions and conveniences to meet all of their varied needs. This is as harmonious as it gets.”

About DSG

DSG, Inc. supports clinical data capture and management with a proprietary, organically integrated suite of award-winning user-friendly technology solutions, including flagship eCaseLink™ EDC, Risk-Based Monitoring, eSource, ePRO, IWRS, Clinical Supply Systems, Safety System, and CTMS. Since 1992, DSG has successfully supported thousands of clinical trials for over 400 companies and 25,000 sites across 93 countries, headquartered in Malvern, Pa., with additional offices in the U.S. and Asia: www.dsg-us.com.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market five oncology drugs- FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights; MARQIBO® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, for which the Company has worldwide marketing rights and BELEODAQ® (belinostat) for Injection in the U.S.. Spectrum’s strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.

All products and services above are the property of their respective owners.